Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial
47.8% were improved but still sick, 1.3% were the same, and 0.1% were worse. Of the 96 patients assessed as not cured, mothers reported that 4.2% were completely well, 63.5% were improved but still sick, 29.2% were the same, and 3.1% were worse, (p=0.001).
Clinical conclusions
Treatment with oral amoxicillin for 3 days was as effective as treatment for 5 days in children with non-severe pneumonia.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the economic evaluation. In effect, a cost-consequences analysis was conducted.
Direct costs
The perspective of the payer was adopted. The total direct medical costs estimated were for drugs, investigations, hospitalisation, procedures and consultations, and out-of-pocket expenditures. The resource data were collected from children who did not respond to treatment or who relapsed. The unit costs were derived from actual prices from three randomly selected hospitals. Averaged unit prices were used in the analysis. The resource quantities and the costs were not reported separately and the price year was not reported. The costs were not discounted since the duration of followup was less than one year.
Statistical analysis of costs
A univariate analysis was performed to compare the direct medical costs in the two treatment groups. Student's t-test was used.
Indirect Costs
The indirect costs were not included. This was consistent with the perspective adopted.
Currency
Indian rupees (R). The costs were also evaluated in UK pounds sterling () and US dollars ($), but no conversion rates were given.
Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The mean direct medical cost of treating those who had not responded to treatment or who had relapsed was R272.79 in both treatment groups.
The average direct medical costs of treating 1,000 cases of non-severe pneumonia with amoxicillin would be R54,930 (790, $1,100) for 3 days' treatment and R62,430 (900, $1,250) for 5 days' treatment.
Not applicable due to the cost-consequences approach taken.
Authors' conclusions
Treatment with oral amoxicillin for 3 days was as effective as treatment for 5 days in children with non-severe pneumonia. It was also cheaper, with increased adherence and possible decreased emergence of antimicrobial resistance.
CRD COMMENTARY -Selection of comparators
The reason for the choice of the comparators was clear. Amoxicillin has been recommended as a suitable alternative to co-trimoxazole. You should consider whether amoxicillin is a widely used treatment in your own setting.
Validity of estimate of measure of effectiveness
The basis of the analysis was a prospective, randomised, double-blinded study, which was appropriate for the study question. The use of power calculations was reported. It was unclear whether the study sample was representative of the study population, as children with asthma and with severe disease were excluded and the causes of infection were not investigated. The patients were shown to have been comparable at analysis, so confounding should be low. Selection bias is likely to have been low due to randomisation. The authors reported that the duration of follow-up (15 days) may have been too short to show any difference in outcomes between the two treatment regimens. Overall, the internal validity should be fairly good.
Validity of estimate of measure of benefit
There was no summary measure of benefit since, in effect, a cost-consequences analysis was conducted.
Validity of estimate of costs
The perspective of the payer was adopted and, as such, all the relevant categories of costs appear to have been included in the analysis. However, no unit costs or resource quantities were reported and only limited details of the methods of cost estimation were given. The cost estimates are likely to be specific to the Indian setting and sensitivity analyses were not performed. The price year was not reported. These facts hinder the reproducibility of the results in other settings. The costs were treated stochastically. Although the authors reported the total costs in rupees, UK pounds sterling and US dollars, no conversion rates were reported. No discounting was performed since the duration of follow-up was less than one year.
